Navigation Links
PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
Date:10/21/2009

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced its participation at the 8th Annual Partnerships in Clinical Trials Conference taking place at the World Trade Center in Rotterdam, The Netherlands from November 3-6, 2009.

At the conference, top management will discuss some of the most important issues to impact the industry growth and financial performance of CROs and their clients: the changing marketplace for drug development services, the industry's move to the fast growing emerging markets, and the clinical implications of developing biosimilar therapeutics.

Wednesday, 4 November 2009

Jeffrey P. McMullen, President and CEO of PharmaNet Development Group, will give a keynote presentation, "CRO Growth Opportunities in a More Challenging Market Environment."

Dr. Robert Reekie, Senior Executive Vice President Operations, Europe, Asia-Pacific, will chair a session entitled "Emerging Economies - Your Strategic Expansion for Cost Reduction and Patient Recruitment."

Thursday, 5 November 2009

Dr. Pablo Fernandez, Senior Vice President, Medical Affairs, will present "A Practical Overview of Outsourced Clinical Development for Biosimilars."

Conference attendees are invited to visit booth number 94 where PharmaNet Development Group's international team of experts will discuss how the Company helps clients reach their goal of delivering safe and effective therapeutics to patients.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com .

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    Email: ahess@pharmanet.com

SOURCE PharmaNet Development Group, Inc.


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Promising Cystic Fibrosis Compound on Track for Development
5. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
6. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
7. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
8. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
9. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
10. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
11. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/7/2017)... Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), ... the quarter ended June 30, 2017.  All comparisons, unless otherwise ... Second Quarter 2017 Highlights ... to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)... 4, 2017 The search for test results ... physician/patient consult has long been the goal of healthcare ... focus of the largest meeting of lab professionals and ... market research firm Kalorama Information.  The firm said scores ... or related supplies and software were at the American ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... 16, 2017 , ... Any Lab Test Now® is thrilled to ... the newly released, 36th annual Inc. 5000 , the most prestigious compilation of ... successful companies within the American economy’s most dynamic segment — its independent small and ...
(Date:8/16/2017)... ... August 16, 2017 , ... In a recent survey, eighty-two percent of women ... In fact, cellulite can't always be eliminated by diet and exercise alone, and now ... select physicians nationwide. Dr. Kenneth Rothaus has recently added Cellulaze™ to his ...
(Date:8/16/2017)... Island, NY (PRWEB) , ... August 16, 2017 , ... ... with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical ... takes much of the guesswork out of a needle stick and more importantly, helps ...
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the ... from around the world, is excited to announce Andrew Ly as the winner of ... pursuits, covering textbook costs. , Ly, who is in his third year at ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection Control ... cycle, both between patient procedures and before storage, is a requisite practice crucial ... to the prevention of disease transmission and nosocomial infection as cleaning and HLD.” ...
Breaking Medicine News(10 mins):